Age: 34.0
Sex: F
Vaccine: COVID19
Symptoms: Exposure during pregnancy, Maternal exposure before pregnancy
Clinical narrative: Patient received the Moderna COVID-19 vaccine before pregnancy; vaccine exposure during pregnancy; This spontaneous prospective pregnancy case was reported by a pharmacist and describes the occurrence of MATERNAL EXPOSURE BEFORE PREGNANCY (Patient received the Moderna COVID-19 vaccine before pregnancy) and EXPOSURE DURING PREGNANCY (vaccine exposure during pregnancy) in a 34-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 019B21A and 026D21A) for COVID-19 vaccination.     No Medical History information was reported.   On 05-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 24-Oct-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. The patient's last menstrual period was on 15-Mar-2021 and the estimated date of delivery was 06-Jan-2022. On an unknown date, the patient experienced MATERNAL EXPOSURE BEFORE PREGNANCY (Patient received the Moderna COVID-19 vaccine before pregnancy) and EXPOSURE DURING PREGNANCY (vaccine exposure during pregnancy). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) during pregnancy.  At the time of the report, MATERNAL EXPOSURE BEFORE PREGNANCY (Patient received the Moderna COVID-19 vaccine before pregnancy) and EXPOSURE DURING PREGNANCY (vaccine exposure during pregnancy) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   The patient did not have any adverse events to the prior doses of the Moderna COVID-19 vaccine.  The second and third dose of the vaccine was administered at 3 and 32 weeks of gestation respectively  No concomitant medication information was provided by the reporter.  This spontaneous report concerns a 34 year old female subject with no relevant medical history who was administered mRNA-1273 vaccine before and during pregnancy. The subject was administered the first, second and the third doses of the mRNA-1273 vaccine. The first dose of vaccine was administered 10 days before the last menustrual period. The second and third dose of the vaccine was administered at 3 and 32 weeks of gestation respectively. As per the report, the mother did not experience any adverse event after any of the vaccine doses. The benefit-risk relationship of mRNA-1273 is not affected by this report.; Sender's Comments: This spontaneous report concerns a 34 year old female subject with no relevant medical history who was administered mRNA-1273 vaccine before and during pregnancy. The subject was administered the first, second and the third doses of the mRNA-1273 vaccine. The first dose of vaccine was administered 10 days before the last menustrual period. The second and third dose of the vaccine was administered at 3 and 32 weeks of gestation respectively. As per the report, the mother did not experience any adverse event after any of the vaccine doses. The benefit-risk relationship of mRNA-1273 is not affected by this report.